ArticleFrontiers in medicine2021
Case Report: Rare Pulmonary Sclerosing Pneumocytoma: Large, Multiple, Metastatic, and Fatal.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 21 citations in OpenAlex.
- Pulmonary sclerosing pneumocytoma with rapid progression: a case description of serial images.Quantitative imaging in medicine and surgery · 2025Article
- Pulmonary Sclerosing Pneumocytoma: A Case Revealed During 8-year of Follow-up with CT Imaging.Internal medicine (Tokyo, Japan) · 2025Article
- Successful immunotherapy with ipilimumab and nivolumab in a patient with pulmonary sclerosing pneumocytoma.International cancer conference journal · 2025Article
- Revisiting Pulmonary Sclerosing Pneumocytoma.Clinics and practice · 2024Review
- Pulmonary sclerosing pneumocytoma - approaching a solitary pulmonary nodule and the limitations of risk prediction models.BMJ case reports · 2023Article
- Giant pulmonary sclerosing pneumocytoma with potentially malignant biological behavior: a case report and literature review.Annals of translational medicine · 2023Article
- Pulmonary sclerosing pneumocytoma and mortality risk.BMC pulmonary medicine · 2022Review
- Clinical Characteristics of Malignant Pulmonary Sclerosing Pneumocytoma Based on a Study of 46 Cases Worldwide.Cancer management and research · 2022Article
- Case report: Rare epithelioid hemangioendothelioma occurs in both main bronchus and lung.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary sclerosing pneumocytoma (PSP) is a rare benign or low-grade malignant tumor, but it has the potential to present with multiple lesions, lymph node metastasis, extra-pulmonary metastasis, recurrence and even cause death. Herein, a case of PSP that was huge, presented with multiple lesions and had lymph node as well as extrapulmonary metastases (liver, abdominal cavity, bones) is reported for the first time. This patient was also the first one to die of respiratory and circulatory failure caused by the PSP tumor and its metastases which compressed the mediastinal tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.